0 79

Cited 0 times in

Cited 0 times in

Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia

DC Field Value Language
dc.contributor.author최진섭-
dc.contributor.author최기홍-
dc.contributor.author김남규-
dc.contributor.author백승혁-
dc.contributor.author민병소-
dc.contributor.author안중배-
dc.contributor.author정민규-
dc.contributor.author신상준-
dc.date.accessioned2025-08-14T05:03:19Z-
dc.date.available2025-08-14T05:03:19Z-
dc.date.issued2013-11-
dc.identifier.issn0030-2414-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/207022-
dc.description.abstractBackground: Converting chemotherapy followed by surgery is known to be associated with improved clinical outcomes in colorectal cancer (CRC) patients with hepatic metastasis. This study is to investigate the clinicopathological prognostic factors for disease-free survival (DFS) after curative resection of primary and metastatic lesions. Methods: We retrospectively analyzed the medical records of 76 CRC patients who had initially had unresectable hepatic metastasis, which was considered resectable after systemic chemotherapy, and had undergone curative surgery in the period from January 2006 to December 2011. DFS was compared by assessing clinical data including age, sex, staging, number of hepatic lesion(s), size of the largest hepatic lesion and serum carcinoembryonic antigen (CEA) levels. Results: The median age was 57 years and 47 patients were male. The median DFS was 10.4 months. Multivariate Cox regression analysis revealed that age <50 years (HR 2.70, 95% CI 1.43-5.10, p = 0.002) and CEA elevation after curative surgery (HR 2.20, 95% CI 1.11-4.36, p = 0.023) were associated with a shorter DFS. Conclusions: Given that patients <50 years old or with elevated CEA levels after curative surgery demonstrated a short DFS, additional postoperative systemic treatment or active surveillance, at least, should strongly be considered for this group.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherKarger-
dc.relation.isPartOfONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntibodies, Monoclonal, Humanized / administration & dosage-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols / administration & dosage-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols / therapeutic use*-
dc.subject.MESHBevacizumab-
dc.subject.MESHBiomarkers, Tumor / blood*-
dc.subject.MESHCamptothecin / administration & dosage-
dc.subject.MESHCamptothecin / analogs & derivatives-
dc.subject.MESHCarcinoembryonic Antigen / blood*-
dc.subject.MESHCetuximab-
dc.subject.MESHColectomy*-
dc.subject.MESHColorectal Neoplasms / drug therapy-
dc.subject.MESHColorectal Neoplasms / mortality-
dc.subject.MESHColorectal Neoplasms / pathology*-
dc.subject.MESHColorectal Neoplasms / surgery-
dc.subject.MESHColorectal Neoplasms / therapy*-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHFluorouracil / administration & dosage-
dc.subject.MESHHumans-
dc.subject.MESHLeucovorin / administration & dosage-
dc.subject.MESHLiver Neoplasms / drug therapy-
dc.subject.MESHLiver Neoplasms / mortality-
dc.subject.MESHLiver Neoplasms / secondary*-
dc.subject.MESHLiver Neoplasms / surgery-
dc.subject.MESHLiver Neoplasms / therapy*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMultivariate Analysis-
dc.subject.MESHNeoadjuvant Therapy / methods*-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHOrganoplatinum Compounds / administration & dosage-
dc.subject.MESHPredictive Value of Tests-
dc.subject.MESHPrognosis-
dc.subject.MESHProportional Hazards Models-
dc.subject.MESHRepublic of Korea / epidemiology-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRisk Assessment-
dc.subject.MESHRisk Factors-
dc.subject.MESHTreatment Outcome-
dc.titlePrognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학교실)-
dc.contributor.googleauthorJun Ho Yi-
dc.contributor.googleauthorHyunki Kim-
dc.contributor.googleauthorMinkyu Jung-
dc.contributor.googleauthorSang Joon Shin-
dc.contributor.googleauthorJin Sub Choi-
dc.contributor.googleauthorGi-Hong Choi-
dc.contributor.googleauthorSeung Hyuk Baik-
dc.contributor.googleauthorByung Soh Min-
dc.contributor.googleauthorNam Kyu Kim-
dc.contributor.googleauthorJoong Bae Ahn-
dc.identifier.doi10.1159/000355475-
dc.contributor.localIdA04199-
dc.contributor.localIdA04046-
dc.contributor.localIdA00353-
dc.contributor.localIdA01827-
dc.contributor.localIdA01402-
dc.contributor.localIdA02262-
dc.contributor.localIdA03606-
dc.contributor.localIdA02105-
dc.relation.journalcodeJ02416-
dc.identifier.eissn1423-0232-
dc.identifier.pmid24217184-
dc.identifier.urlhttps://karger.com/ocl/article/85/5/283/239072/Prognostic-Factors-for-Disease-Free-Survival-after-
dc.contributor.alternativeNameChoi, Jin Sub-
dc.contributor.affiliatedAuthor최진섭-
dc.contributor.affiliatedAuthor최기홍-
dc.contributor.affiliatedAuthor김남규-
dc.contributor.affiliatedAuthor백승혁-
dc.contributor.affiliatedAuthor민병소-
dc.contributor.affiliatedAuthor안중배-
dc.contributor.affiliatedAuthor정민규-
dc.contributor.affiliatedAuthor신상준-
dc.citation.volume85-
dc.citation.number5-
dc.citation.startPage283-
dc.citation.endPage289-
dc.identifier.bibliographicCitationONCOLOGY, Vol.85(5) : 283-289, 2013-11-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.